Table 3 Characteristics of bronchoalveolar lavage in normal subjects and patients with SARS
Normal subjects | SARS patients | ||
|---|---|---|---|
60 days | 90 days | ||
(n = 9) | (n = 12) | (n = 6) | |
Age (years) | 24.1 ± 2.2 | 34.0 ± 2.7* | 36.6 ± 3.9 |
Female gender | 5 | 4 | 3 |
Cellularity (104 cells/ml) | 9.6 ± 0.9 | 32.9 ± 9.0* | 26.2 ± 9.1 |
Cell viability (%) | 91.5 ± 4.3 | 90.4 ± 1.3 | 91.6 ± 1.8 |
AM (%) | 93.2 ± 1.2 | 88.8 ± 1.2* | 95.0 ± 0.6† |
AM (104 cells/ml) | 8.9 ± 0.8 | 29.0 ± 7.8* | 25.1 ± 9.8 |
Lymphocytes (%) | 5.9 ± 1.2 | 10.2 ± 1.2* | 4.1 ± 0.5† |
Lymphocytes (104 cells/ml) | 0.6 ± 0.1 | 3.8 ± 1.2* | 1.0 ± 0.2† |
Neutrophils (%) | 0.9 ± 0.2 | 0.7 ± 0.2 | 0.9 ± 0.6 |
Neutrophils (104 cells/ml) | 0.1 ± 0.02 | 0.2 ± 0.1 | 0.2 ± 0.1 |
Eosinophils (%) | 0.1 ± 0.1 | 0.3 ± 0.2 | 0.0 ± 0.0 |
Eosinophils (104 cells/ml) | 0.01 ± 0.01 | 0.05 ± 0.04 | 0.0 ± 0.0 |